Author archive for Admin Isofol

  • aside

    Positive treatment results with Modufolin® (arfolitixorin) will be published at a cancer congress (ASCO) in the US

    Prior to this year’s Gastrointestinal (GI) Cancers Symposium of the American Society of Clinical Oncology (ASCO), the worlds leading oncology…

    by
  • aside

    Successful End-of-Phase 2 meeting with FDA and Phase 3 Program for Modufolin® agreed

    Isofol Medical AB (publ), developing Modufolin®(arfolitixorin) as treatment for advanced colorectal cancer, has had a successful regulatory meeting with the…

    by
  • aside

    Isofol reports positive efficacy data for Modufolin® (arfolitixorin) from patients treated for metastatic colorectal cancer

    Isofol Medical AB (publ), a clinical oncology company, reports efficacy data for Modufolin® (arfolitixorin) from patients treated during 16 weeks…

    by
  • aside

    Isofol to present at the 10th Annual Biotech Showcase Conference

    January 4 2017 Isofol Medical AB (publ), a clinical oncology company, announces that Chief Executive Officer Anders Rabbe and Chief…

    by
  • aside

    Isofol attends the French-Swedish Life Science Day 2017

    The French-Swedish Life Science Day 2017 conference gathers highly innovative biotech companies from Sweden, French and Swedish life science investors…

    by
  • aside

    Isofol announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment will be presented at ASCO-GI 2018

    Isofol Medical AB (publ) announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment has been accepted for presentation…

    by
  • aside

    Isofol appoints Gustaf Albèrt as Chief Financial Officer

    Isofol Medical AB (publ) has recruited Gustaf Albèrt as Chief Financial Officer. With extensive experience from leading financial positions, Albèrt…

    by
  • aside

    Isofol announces that Modufolin® as a rescue therapy in the treatment of osteosarcoma in children is safe and preventive of HDMTX toxicities

    Isofol Medical AB (publ) announces that results from the clinical ISO-MTX-003 study suggest that Modufolin® as a rescue therapy, in…

    by
  • aside

    Isofol Medical announces successful Type C meeting with FDA regarding its drug candidate, Modufolin® for treatment of metastatic colorectal cancer

    Isofol Medical AB (publ) announces the completion of a successful Type-C meeting with the FDA in preparation for the pivotal…

    by
  • aside

    From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin® in patients with metastatic colorectal cancer

    Isofol Medical AB (publ), a clinical oncology company, announces that the initial indications of Modufolin® efficacy in the ISO-CC-005 study…

    by